Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation-Case Report and a Literature Review.

Current oncology (Toronto, Ont.) - 13 May 2022

Rekowska Anna, Rola Piotr, Wójcik-Superczyńska Magdalena, Chmielewska Izabela, Krawczyk Paweł, Milanowski Janusz

Abstract excerpt

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related mortality worldwide. It is responsible for 80-85% of lung cancer cases. NSCLC can be divided into several groups, led by adenocarcinoma (ADC)-40-50% and squamous cell carcinoma (SCC)-20-30%. The development of new molecular therapies targeting particular abnormalities such as mutations in the EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Genes, erbB-1

Share to Positron Emission Tomography Computed Tomography

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35621675
DOI: 10.3390/curroncol29050285
PMCID: PMC9140000

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation-Case Report and a Literature Review.PMID 35621675Read ↗

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.Semantic proximity Read ↗

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.Semantic proximity Read ↗

The treatment of advanced lung adenocarcinoma with activating EGFR mutations.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care.Semantic proximity Read ↗

The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis.Semantic proximity Read ↗

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.Semantic proximity Read ↗

Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients.Semantic proximity Read ↗

Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant ( L833V / H835L ) lung adenocarcinoma patient: a case report.Semantic proximity Read ↗

Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report.Semantic proximity Read ↗

De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.